Wyllie Cornwell - Pfizer Independent Director
| PFE Stock | EUR 24.59 0.07 0.28% |
Director
Mr. Wyllie Don Cornwell is an Independent Director of Pfizer Inc. He was Chairman of the Board and Chief Executive Officer of Granite Broadcasting Corporation from 1988 until his retirement in August 2009, and served as Vice Chairman of the Board until December 2009. Director of American International Group, Inc. and Avon Products, Inc. Director of the Edna McConnell Clark Foundation. Director of the Wallace Foundation from 2002 until 2012 and previously served as a Director of CVS Caremark for over 10 years. Trustee of Big Brothers Big Sisters of New York City. Through Mr. Cornwells 38year career as an entrepreneur driving the growth of a consumerfocused media company, an executive in the investment banking industry and a director of several significant consumer product and healthcare companies, he has valuable business, leadership and management experience and brings important perspectives on the issues facing Pfizer. Mr. Cornwell founded and built Granite, a consumerfocused media company, through acquisitions and operating growth, enabling him to provide insight and guidance on strategic direction and growth since 1997.
| Age | 70 |
| Tenure | 27 years |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1287 % which means that it generated a profit of $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3622 %, meaning that it generated $0.3622 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Peter Murphy | NorAm Drilling AS | 55 | |
| Douglas Harrison | Superior Plus Corp | 58 | |
| Mary Jordan | Superior Plus Corp | 58 | |
| Robert Engbloom | Superior Plus Corp | 64 | |
| Michael Kreger | NorAm Drilling AS | 33 | |
| James Arestia | NorAm Drilling AS | N/A | |
| Randall Findlay | Superior Plus Corp | 67 | |
| Richard Bradeen | Superior Plus Corp | 61 | |
| Patrick Gottschalk | Superior Plus Corp | 54 | |
| Laura Walker | NorAm Drilling AS | 60 | |
| Peter Kern | NorAm Drilling AS | 50 | |
| Catherine Best | Superior Plus Corp | 64 | |
| Walentin Mirosh | Superior Plus Corp | 71 | |
| David Smith | Superior Plus Corp | 59 | |
| Eugene Bissell | Superior Plus Corp | 64 | |
| Craig Jacobson | NorAm Drilling AS | 65 | |
| Ross Levinsohn | NorAm Drilling AS | 54 | |
Management Performance
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President - Global Established Pharma Business | ||
| Jennifer Damico, Controller VP | ||
| Frank DAmelio, CFO, Executive Vice President - Business Operations | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
| Helen Hobbs, Independent Director | ||
| Shantanu Narayen, Director | ||
| James Smith, Director | ||
| Christopher CFA, VP Officer | ||
| Dennis Ausiello, Independent Director | ||
| Mikael Dolsten, President - Worldwide Research and Development | ||
| Frances Fergusson, Independent Director | ||
| Stephen Sanger, Independent Director | ||
| Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
| Wyllie Cornwell, Independent Director | ||
| Suzanne Johnson, Independent Director | ||
| David Denton, Chief VP | ||
| Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
| DVM DVM, Chairman CEO | ||
| Geno Germano, Group President - Global Innovative Pharma Business | ||
| Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
| Sally Susman, Executive Vice President - Corporate Affairs | ||
| Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Freda LewisHall, Executive Vice President Chief Medical Officer | ||
| Rady Johnson, Executive Vice President Chief Compliance and Risk Officer | ||
| Mikael MD, Dev Research | ||
| Dan Littman, Director | ||
| Ian Read, Chairman of the Board, CEO | ||
| James Kilts, Independent Director | ||
| Don Cornwell, Independent Director | ||
| Charles Hill, Executive Vice President - Worldwide Human Resources | ||
| Joseph Echevarria, Director | ||
| Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
| Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Angela Hwang, Group President - Pfizer Essential Health | ||
| Scott Gottlieb, Director | ||
| Ronald Blaylock, Independent Director | ||
| Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
| Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 276.06 B | |||
| Shares Outstanding | 5.62 B | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 71.00 % | |||
| Price To Earning | 16.17 X | |||
| Price To Book | 3.13 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |